Chinese Academy of

A compound glutamine capsule is a small-molecule therapeutic candidate in Phase 3 development for the treatment of mucositis, sponsored by Xiyuan Hospital of China Academy of Chinese Medical Sciences. The program, identified as internal code 2021-615, is being evaluated against simulated placebo in a randomized controlled trial. Mucositis—inflammation and ulceration of the oral and gastrointestinal mucosa—represents a significant adverse effect in cancer patients undergoing chemotherapy and radiation therapy, with limited effective preventive and therapeutic options. The most recent milestone was recorded on 25 October 2021. The compound is currently in active clinical development with the primary trial registered as NCT05092113. The sponsor has not disclosed the specific mechanism of action, molecular target, or route of administration for this formulation. Regulatory status remains limited to clinical trial phase in China, with no approval or filing disclosed to date. The development strategy appears focused on establishing efficacy through Phase 3 comparative evidence against placebo, though expected timelines for regulatory submission or approval have not been disclosed.

Oral mucositis affects 30–90% of cancer patients receiving chemotherapy or head-and-neck radiation, causing severe pain, difficulty eating and swallowing, increased infection risk, and treatment interruptions that compromise oncologic outcomes. Current management relies primarily on supportive care and palliative measures; no disease-modifying preventive therapy has achieved widespread clinical adoption. The unmet medical need is substantial, particularly in developing markets where access to advanced supportive care technologies remains limited. Glutamine supplementation has been investigated for decades as a potential mucoprotective agent based on its role as a primary fuel for rapidly dividing intestinal epithelial cells; however, clinical evidence remains mixed and inconsistent across trials. The competitive landscape includes both pharmacologic approaches (small-molecule therapeutics such as GC4419 from Galera Therapeutics in Phase 3, clonidine buccal tablets from Monopar in Phase 3) and device-based interventions (low-intensity laser therapy already approved). Xiyuan Hospital's portfolio reveals multiple concurrent mucositis programs, suggesting a strategic focus on this indication. The patient population is large and growing, encompassing millions of cancer patients annually worldwide. Commercial significance is moderate to substantial, as any effective preventive therapy could achieve rapid adoption in oncology centers globally, though market size remains constrained by the supportive-care nature of the indication and competition from established palliative approaches.

Drug Class: Small-molecule oral capsule formulation.

Modality: Small molecule.

Mechanism of Action: Not yet disclosed.

Molecular Target: Not yet disclosed.

Route of Administration: Oral (capsule).

Therapeutic Class: Mucoprotective agent.

Related Therapies: Glutamine supplementation has been studied for gastrointestinal mucoprotection in critical illness and cancer therapy. The sponsor is also investigating glutamine combined with thalidomide, steroid nasal spray formulations, and spirulina-derivative sprays for mucositis, suggesting a multi-modal development strategy. Competing approaches include GC4419 (a free radical scavenger in Phase 3), clonidine HCl buccal tablets (Phase 3), low-intensity laser therapy (approved), and various herbal and botanical formulations.

First Approval: Not yet disclosed; program remains in Phase 3 clinical trials.

Patent Status: Not yet disclosed.

China (NMPA): The compound glutamine capsule is in clinical trials status in China. No regulatory filing, approval, or expedited designation has been disclosed. The program is identified with NCT05092113 as the primary trial registration.

United States (FDA): No FDA regulatory activity, IND status, or development pathway has been disclosed.

European Union (EMA): No EMA regulatory activity or development pathway has been disclosed.

Japan (PMDA): No PMDA regulatory activity has been disclosed.

Regulatory Status Summary: The compound remains in active clinical development with regulatory status limited to China. Expected timelines for regulatory submission, approval, or label expansion have not been disclosed. No breakthrough therapy, fast-track, or priority review designations are mentioned in the available facts.

Strategic Positioning: Xiyuan Hospital's multi-program portfolio in mucositis suggests a deliberate strategy to capture market share across multiple therapeutic modalities and mechanisms. The glutamine capsule represents a pharmacologic approach to a large unmet need, but the sponsor's concurrent development of glutamine-thalidomide combinations, topical steroids, and botanical formulations indicates hedging against single-program risk and potential for combination or sequential therapy strategies.

Competitive Implications: The glutamine capsule faces significant competition from GC4419 (Galera), which has demonstrated clinical efficacy as a free radical scavenger and may benefit from first-mover advantage in Phase 3. Clonidine buccal tablets (Monopar) offer a different mechanism and route. The approved low-intensity laser therapy establishes a non-pharmacologic standard. Xiyuan's internal competition from glutamine-thalidomide and other formulations may cannibalize market share if multiple candidates advance to approval. The sponsor must differentiate on efficacy, safety profile, and ease of administration.

Clinical Evidence Gaps: No trial results have been reported for any of the four registered NCT IDs associated with the glutamine capsule program. Mechanism of action and molecular target remain undisclosed, limiting scientific differentiation. Comparative efficacy data against active controls (rather than placebo) would strengthen competitive positioning.

Future Catalysts: Phase 3 trial results publication or regulatory submission would be key milestones. Interim efficacy or safety data could accelerate or delay development. Regulatory feedback from NMPA on trial design or endpoints may influence timelines. Approval or rejection of competing programs (particularly GC4419) will reshape the competitive landscape.

Commercial Considerations: Mucositis is a supportive-care indication with moderate commercial potential; peak sales are unlikely to exceed $200–500 million annually for any single agent given market fragmentation and the availability of approved alternatives. Xiyuan's focus on the Chinese market may limit global commercial reach unless partnerships with multinational pharma are established.